Simone Wielders

Technical staff

Simone Wilders has been working as technician at the Department of Biochemistry of Maastricht University since 1988.

The first 10 years, she was involved in the development of the automatic measurement of thrombin generation in plasma at the group of Prof. Coen Hemker. The next 10 years, she developed and performed analysis on the blood-material interface and investigated the interaction between blood platelet activation and the coagulation system at the group of Dr Theo Lindhout. For four years she has worked at the group of Dr Gerry Nicolaes on expression and characterisation of recombinant variants of coagulation proteins. At the group of Dr Elisabetta Castoldi, she has studied for 4 years coagulation Factor V deficiency and the interaction between FV and TFPIa. Since 2017, she has been working at the laboratory for clinical thrombosis and hemostasis of Prof. Hugo ten Cate and has been involved in clinical oriented studies.

Furthermore, Simone performs education and management tasks and she is prevention officer and biological safety expert of the Department of Biochemistry.

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: H4.302
T: +31(0)43 388 42 83

  • 2022
    • Karel, M. F. A., Lemmens, T. P., Tullemans, B. M. E., Wielders, S. J. H., Gubbins, E., van Beurden, D., van Rijt, S., & Cosemans, J. M. E. M. (2022). Characterization of Atherosclerotic Plaque Coating for Thrombosis Microfluidics Assays. Cellular and Molecular Bioengineering, 15(1), 55-65.
  • 2019
    • van Doorn, P., Rosing, J., Wielders, S. J., Hackeng, T. M., & Castoldi, E. (2019). Corrigendum: The C-terminus of tissue factor pathway inhibitor-a inhibits factor V activation by protecting the Arg(1545) cleavage site (vol 15, pg 140, 2017). Journal of Thrombosis and Haemostasis, 17(7), 1195-1195.
  • 2017
    • van Doorn, P., Rosing, J., Wielders, S. J., Hackeng, T. M., & Castoldi, E. (2017). The C-terminus of tissue factor pathway inhibitor-alpha inhibits factor V activation by protecting the Arg(1545) cleavage site. Journal of Thrombosis and Haemostasis, 15(1), 140-149.
  • 2016
    • Cheung, Y. W., Bouman, A. C., Castoldi, E., Wielders, S. J., Spronk, H. M. H., ten Cate, H., Hoek - ten Cate, A., & ten Wolde, M. (2016). Toll-like receptor 9 gene expression in the post-thrombotic syndrome, residual thrombosis and recurrent deep venous thrombosis: A case-control study. Thrombosis Research, 140, 106-109.
  • 2015
    • Nuzzo, F., Bulato, C., Nielsen, B. I., Lee, K., Wielders, S. J., Simioni, P., Key, N. S., & Castoldi, E. (2015). Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency. Haemophilia, 21(2), 241-248.
    • Dargaud, Y., Scoazec, J. Y., Wielders, S. J. H., Trzeciak, C., Hackeng, T. M., Negrier, C., Hemker, H. C., Lindhout, T., & Castoldi, E. (2015). Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation. Blood, 125(9), 1497-1501.
  • 2014
    • Sperandio, O., Wildhagen, K. C. A. A., Schrijver, R., Wielders, S., Villoutreix, B. O., & Nicolaes, G. A. F. (2014). Identification of novel small molecule inhibitors of activated protein C. Thrombosis Research, 133(6), 1105-1114.
    • Nicolaes, G. A. F., Kulharia, M., Voorberg, J., Kaijen, P. H., Wroblewska, A., Wielders, S., Schrijver, R., Sperandio, O., & Villoutreix, B. O. (2014). Rational design of small molecules targeting the C2 domain of coagulation factor VIII. Blood, 123(1), 113-120.
  • 2013
    • Schuijt, T. J., Bakhtiari, K., Daffre, S., DePonte, K., Wielders, S. J. H., Marquart, J. A., Hovius, J. W., van der Poll, T., Fikrig, E., Bunce, M. W., Camire, R. M., Nicolaes, G. A. F., Meijers, J. C. M., & van 't Veer, C. (2013). Factor Xa Activation of Factor V Is of Paramount Importance in Initiating the Coagulation System: Lessons From a Tick Salivary Protein. Circulation, 128(3), 254-266.
  • 2004
    • Keuren, J. F. W., Wielders, S. J. H., Driessen, A., Verhoeven, M., Hendriks, M., & Lindhout, T. (2004). Covalently-bound heparin makes collagen thromboresistant.Arteriosclerosis Thrombosis and Vascular Biology, 24(3), 613-617.